Drug Trial Radar · NCT00972777
Efficacy of Besifloxacin Ophthalmic Suspension in the Treatment of Bacterial Conjunctivitis
Last checked: Nov 20, 2026Latest source record: Mar 29, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
474
Actual
Start
Oct 2009
Primary completion
Oct 2010
Study completion Feb 2011
Sponsor
- Lead sponsor
- Bausch & Lomb IncorporatedIndustry
- Sponsor type
- Industry
- First posted
- Sep 9, 2009
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 1 year
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is being conducted to evaluate the clinical and microbial efficacy of besifloxacin ophthalmic suspension compared with vehicle in the treatment of bacterial conjunctivitis. This study was conducted as a phase IIb study and continued with further enrollment as a phase III study.
Conditions
- Bacterial Conjunctivitis
Interventions
BesifloxacinDrug
Besifloxacin 0.6% administered into the study eye two times a day for three days.
Vehicle (Placebo)Drug
Vehicle administered to the study eye two times a day for three days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical ResolutionTime frame: Visit 2
- Microbial EradicationTime frame: Visit 2
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bausch & Lomb Incorporated
Rochester, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.